Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinat...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2021
|
| _version_ | 1797067323117404160 |
|---|---|
| author | Skelly, DT Harding, AC Gilbert-Jaramillo, J Knight, M Longet, S Brown, A Adele, S Adland, E Brown, H Medawar Laboratory Team Tipton, T Stafford, L Johnson, S Amini, A OPTIC Clinical Group Kit Tan, T Schimanski, L Huang, K-Y Rijal, P PITCH Study Group Cmore Phosp-C Group Frater, J Goulder, P Conlon, C Jeffery, K Dold, C Pollard, A Sigal, A Oliveira, TD Townsend, A Klenerman, P Dunachie, S Barnes, E Carroll, M James, WS |
| author_facet | Skelly, DT Harding, AC Gilbert-Jaramillo, J Knight, M Longet, S Brown, A Adele, S Adland, E Brown, H Medawar Laboratory Team Tipton, T Stafford, L Johnson, S Amini, A OPTIC Clinical Group Kit Tan, T Schimanski, L Huang, K-Y Rijal, P PITCH Study Group Cmore Phosp-C Group Frater, J Goulder, P Conlon, C Jeffery, K Dold, C Pollard, A Sigal, A Oliveira, TD Townsend, A Klenerman, P Dunachie, S Barnes, E Carroll, M James, WS |
| author_sort | Skelly, DT |
| collection | OXFORD |
| description | The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants. |
| first_indexed | 2024-03-06T21:54:37Z |
| format | Journal article |
| id | oxford-uuid:4c7c0b62-9f97-40d5-8ecc-627ca3677983 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:54:37Z |
| publishDate | 2021 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:4c7c0b62-9f97-40d5-8ecc-627ca36779832022-03-26T15:49:53ZTwo doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4c7c0b62-9f97-40d5-8ecc-627ca3677983EnglishSymplectic ElementsSpringer Nature2021Skelly, DTHarding, ACGilbert-Jaramillo, JKnight, MLonget, SBrown, AAdele, SAdland, EBrown, HMedawar Laboratory TeamTipton, TStafford, LJohnson, SAmini, AOPTIC Clinical GroupKit Tan, TSchimanski, LHuang, K-YRijal, PPITCH Study GroupCmore Phosp-C GroupFrater, JGoulder, PConlon, CJeffery, KDold, CPollard, ASigal, AOliveira, TDTownsend, AKlenerman, PDunachie, SBarnes, ECarroll, MJames, WSThe extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants. |
| spellingShingle | Skelly, DT Harding, AC Gilbert-Jaramillo, J Knight, M Longet, S Brown, A Adele, S Adland, E Brown, H Medawar Laboratory Team Tipton, T Stafford, L Johnson, S Amini, A OPTIC Clinical Group Kit Tan, T Schimanski, L Huang, K-Y Rijal, P PITCH Study Group Cmore Phosp-C Group Frater, J Goulder, P Conlon, C Jeffery, K Dold, C Pollard, A Sigal, A Oliveira, TD Townsend, A Klenerman, P Dunachie, S Barnes, E Carroll, M James, WS Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_full | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_fullStr | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_full_unstemmed | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_short | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_sort | two doses of sars cov 2 vaccination induce robust immune responses to emerging sars cov 2 variants of concern |
| work_keys_str_mv | AT skellydt twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT hardingac twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT gilbertjaramilloj twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT knightm twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT longets twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT browna twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT adeles twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT adlande twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT brownh twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT medawarlaboratoryteam twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT tiptont twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT staffordl twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT johnsons twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT aminia twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT opticclinicalgroup twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT kittant twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT schimanskil twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT huangky twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT rijalp twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT pitchstudygroup twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT cmorephospcgroup twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT fraterj twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT goulderp twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT conlonc twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT jefferyk twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT doldc twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT pollarda twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT sigala twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT oliveiratd twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT townsenda twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT klenermanp twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT dunachies twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT barnese twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT carrollm twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT jamesws twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern |